KY-556 is an orally active prodrug of disodium cromoglycate (DSCG) used for the treatment of allergic diseases; it dose-dependently inhibits 48-hour homologous passive cutaneous anaphylaxis (PCA) in rats with a longer duration of action than intravenous DSCG; it tends to inhibit histamine release from actively sensitized rat lung fragments; it prolongs survival time in rat systemic anaphylaxis; and it significantly inhibits increased airway resistance in experimental asthma in rats.